What is the risk of SARS-CoV-2 infection among gout patients? SARSCoV2 COVID19 Coronavirus Gout GoutPatients
By Dr. Sanchari Sinha Dutta, Ph.D.Sep 12 2022Reviewed by Aimee Molineux A recent study published in the journal Arthritis & Rheumatology has revealed that people with gout are at higher risk of severe acute respiratory syndrome coronavirus 2 infection, irrespective of the coronavirus disease 2019 vaccination status.
Previous studies investigating the risk of SARS-CoV-2 infection among gout patients have produced conflicting results. Moreover, none of the studies have evaluated the association between COVID-19 vaccination status and risk of severe infection among gout patients. The participants were followed between December 2020 and October 2021. The main outcome of the study was to assess the risk of SARS-CoV-2 infection among gout patients. In addition, the risk of COVID-19-related hospitalization and death was determined as a secondary outcome.
Risk of infection among vaccinated study population A significantly higher risk of SARS-CoV-2 infection was observed among vaccinated gout patients compared to vaccinated individuals without gout. While a weighted incidence rate of 3.76 per 1000 person months was calculated among individuals without gout, individuals with gout exhibited a weighted incidence rate of 4.68 per 1000 person months.
Regarding the risk of severe COVID-19, a higher rate of hospitalization was observed among gout patients compared to that among individuals without gout. However, no significant difference in mortality rate was observed between individuals with and without gout. All gender-specific associations observed between gout and risk of SARS-CoV-2 and severe COVID-19 were irrespective of the vaccination status.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
COVID-19 and cognitive impairment: neuroinvasive and blood‒brain barrier dysfunction - Journal of NeuroinflammationCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic. Although COVID-19 was initially described as a respiratory disease, there is growing evidence that SARS-CoV-2 is able to invade the brains of COVID-19 patients and cause cognitive impairment. It has been reported that SARS-CoV-2 may have invasive effects on a variety of cranial nerves, including the olfactory, trigeminal, optic, and vagus nerves, and may spread to other brain regions via infected nerve endings, retrograde transport, and transsynaptic transmission. In addition, the blood–brain barrier (BBB), composed of neurovascular units (NVUs) lining the brain microvasculature, acts as a physical barrier between nerve cells and circulating cells of the immune system and is able to regulate the transfer of substances between the blood and brain parenchyma. Therefore, the BBB may be an important structure for the direct and indirect interaction of SARS-CoV-2 with the brain via the blood circulation. In this review, we assessed the potential involvement of neuroinvasion under the SARS-CoV-2 infection, and the potential impact of BBB disorder under SARS-CoV-2 infection on cognitive impairment.
Read more »
BNT162b2 SARS-CoV-2 vaccinations found to reduce incidence of long COVID symptomsResearchers assessed the association between Pfizer-BioNTech’s SARS-CoV-2 BNT162b2 messenger ribonucleic acid (mRNA) vaccination and the incidence of post-COVID-19 symptoms among Israeli adults.
Read more »
SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical useIn a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).
Read more »
Small molecule inhibitor found to be effective against SARS-CoV-2 variantsIn a new study, researchers developed RK-33, a small molecule inhibitor of DDX3, and evaluated its efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs).
Read more »
Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infectionIn a recent study posted to the bioRxiv* preprint server, researchers in Germany and the United Kingdom investigated the interferon responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant and SARS-CoV-2 Omicron sub-variants BA.1 and BA.5, and their efficacy in protecting cells from influenza A virus super-infection.
Read more »
Discovery of antibodies that may eliminate the need for COVID vaccinesIn a recent study published in the journal Communications Biology , researchers evaluated the efficacy of monoclonal antibodies (mAbs) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...
Read more »